Ann Arbor, MI, United States of America

Michael Francis Rafferty



Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 200(Granted Patents)


Location History:

  • N. Bradford, CT (US) (1990)
  • N. Branford, CT (US) (1993)
  • Ann Arbor, MI (US) (1986 - 2006)

Company Filing History:


Years Active: 1986-2006

Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents

Title: Michael Francis Rafferty - Innovator in Calcium Channel Blockers

Introduction

Michael Francis Rafferty is a notable innovator based in Ann Arbor, MI, with an impressive portfolio of 34 patents. His work primarily focuses on developing novel compounds that have significant therapeutic potential.

Latest Patents

One of his latest patents revolves around Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers. This invention offers compounds designed to block calcium channels, with applications in treating various medical conditions such as stroke, cerebral ischemia, head trauma, asthma, amyotrophic lateral sclerosis, and epilepsy. Not only does this patent illustrate his commitment to advancing pharmaceutical science, but it also highlights the creation of pharmaceutical compositions that incorporate these innovative compounds.

Career Highlights

Michael's career includes significant contributions while working at Warner-Lambert Company, where he focused on drug development and channel blocker research, refining his expertise in the pharmaceutical field. His innovative spirit has led to his recognition as a key figure in his domain.

Collaborations

Throughout his career, Michael has collaborated with talented individuals such as Graham Johnson and Yuntao Song. Their combined efforts have led to groundbreaking advancements and reinforced Michael’s impact on calcium channel disorders.

Conclusion

With a robust record of patents and a commitment to medical innovation, Michael Francis Rafferty continues to contribute to the field of pharmacology. His work not only showcases his inventiveness but also serves to improve therapeutic options for patients suffering from critical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…